PHASE 1, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFECT OF CYTOCHROME P450 (CYP) 3A4 INHIBITION ON THE PHARMACOKINETICS (PK) AND SAFETY OF QUIZARTINIB (Q) AND ITS ACTIVE METABOLITE, AC886
EHA Library, Jianke Li,
180700
AN OPEN-LABEL, MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY OF RECOMBINANT HUMAN THROMBOPOIETIN AS AN ADJUNCT AFTER INTENSIVE CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA
EHA Library, Xiao-Hui Sui,
180719
ASPARAGINASE ERWINIA CHRYSANTHEMI EFFECTIVELY DEPLETES PLASMA GLUTAMINE, HAS CLINICAL ACTIVITY, AND IS WELL TOLERATED IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Ashkan Emadi,
180723
PROGNOSTIC SIGNIFICANCE OF SOX2, SOX3, SOX11, SOX14 AND SOX18 GENE EXPRESSION IN DE NOVO ACUTE MYELOID LEUKEMIA (AML) PATIENTS
EHA Library, Natasa Tosic,
180724
ASSOCIATION OF T-, B-, NK AND NKT CELLS WITH THE DURATION, COMPLETENESS AND OTHER CHARACTERISTICS OF REMISSION IN PATIENTS WITH APLASTIC ANEMIA
EHA Library, Olga Rozanova,
180762